Montreal biotech with 'promising' weight-loss drug acquired by Ozempic maker
Novo, which said in an Aug. 10 press release that the deal could be worth as much as US$1.08 billion in cash if certain development and commercial milestones are reached, will add INV-202 to a roster of blockbuster weight-loss medications that includes Ozempic and Wegovy. Following its 2017 approval by the U.S. Food and Drug Administration ,
Both Ozempic and Wegovy are injectable drugs that work by mimicking a hormone that controls blood sugar and suppresses appetite: glucagon-like peptide 1, or GLP-1. Inversago’s drug works a bit differently, though. The drug, which comes in tablet form, suppresses appetite while increasing metabolism and energy expenditure. It works by binding to cannabinoid type 1 receptors in peripheral tissues in the lungs, pancreas, kidneys and liver.
Not everyone is as enthusiastic about weight loss drugs. Some believe the medications constitute a setback for the
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk Acquires Inversago Pharma for Potential $1.08 BillionNovo Nordisk, a leading pharmaceutical company, has acquired Inversago Pharma in a deal that could be worth up to $1.08 billion. This acquisition adds INV-202, a weight-loss medication, to Novo Nordisk's portfolio of blockbuster drugs. INV-202 works by suppressing appetite, increasing metabolism, and binding to cannabinoid type 1 receptors. This acquisition further strengthens Novo Nordisk's position in the weight-loss medication market.
Read more »
Weaker Canada exports to weigh on second quarter growthCanada’s merchandise trade balance recorded its second consecutive monthly deficit on falling exports.
Read more »
Weaker Canada exports to weigh on second quarter growth - BNN BloombergCanada’s merchandise trade balance recorded its second consecutive monthly deficit on falling exports.
Read more »
Endeavour Silver posts net loss of $1.1M in Q2 as inflation and foreign exchange weigh inA roundup of all the mining news in the precious metals sector with a variety of company news, mining sector analysis, newsletter writer insights and executive interviews.
Read more »
In Utah and Kansas, state courts flex power over new laws regulating abortion post-RoeState courts have become hotspots in the national abortion debate as Utah and Kansas courts weigh challenges Tuesday from providers over new laws regulating the procedure, more than a year after the overturning of Roe v. Wade.
Read more »
Novo Nordisk Acquires Inversago Pharma for Potential $1.08 BillionNovo Nordisk, a leading pharmaceutical company, has acquired Inversago Pharma in a deal that could be worth up to $1.08 billion. This acquisition adds INV-202, a weight-loss medication, to Novo Nordisk's portfolio of blockbuster drugs. INV-202 works by suppressing appetite, increasing metabolism, and binding to cannabinoid type 1 receptors. This acquisition further strengthens Novo Nordisk's position in the weight-loss medication market.
Read more »